Simrat Randhawa, who serves as Executive Vice President and Head of Research & Development at Dianthus Therapeutics, Inc. (NASDAQ: DNTH), completed the sale of approximately $2.4 million worth of company common stock on June 1, 2026. These dispositions were executed following the exercise of previously acquired stock options and adhered to a Rule 10b5-1 trading plan that was initially adopted on August 14, 2025.
During this period, Randhawa disposed of a total quantity of 26,530 shares of Dianthus Therapeutics common stock. The sales were executed at weighted average prices ranging from $89.17 to $91.96 per share, resulting in the generation of $2,404,076. It is noteworthy that following these transactions, the stock had declined since its previous close; specifically, the price was reported at $81.52, representing a decrease from the prior closing price of $89.45.
The details of the sales were segmented by price range: 5,428 shares were sold within the band of $89.17 to $90.16; another block of 16,943 shares was disposed of at prices between $90.17 and $91.15; and finally, 4,159 shares were sold in the range of $91.17 to $91.96.
Prior to undertaking these sales, Randhawa had acquired a substantial amount of common stock through the exercise of options. These acquisitions totaled 26,530 shares, for which she paid a cumulative cost of $500,205. Like the subsequent sale, these purchases were also managed under the same established Rule 10b5-1 trading plan.
The initial options exercise involved four distinct award categories and corresponding vesting schedules:
- 3,998 shares: These shares had an exercise price of $8.44 and related to an award that vested 25% on April 25, 2023, with the remaining portion scheduled to vest in equal monthly installments over a period of three years.
- 6,908 shares: This tranche was purchased at an exercise price of $17.88 and stemmed from an award set to vest in equal monthly installments over four years after January 1, 2024.
- 6,249 shares: These were acquired at an exercise price of $21.77, linked to an award vesting in equal monthly installments over four years following May 1, 2024.
- 9,375 shares: The largest group was obtained at an exercise price of $22.07, corresponding to an award that vests in equal monthly installments over four years after January 1, 2025.
In terms of current holdings following the recent liquidation, Randhawa directly retains a holding of 4,000 shares of Dianthus Therapeutics common stock.
Risks
- Stock price decline following executive sale
- Dependency on regulatory updates (FDA)
- Market volatility reflected in short interest increases at peers
More from Insider Trading
Risks
- Stock price decline following executive sale
- Dependency on regulatory updates (FDA)
- Market volatility reflected in short interest increases at peers